here is the English version
DOI: 10.35556/idr-2020-4(93)16-20

Поступила 19.03.2020, после доработки — 08.09.2020

The recurrence rate of pleomorphic adenoma in the long-term follow-up according to the clinic of maxillofacial surgery Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia
Yaremenko A.I., Kutukova S.I., corresponding author: Harutyunyan G.G., Petrov N.L.
Pavlov First Saint Petersburg State Medical University, Russia, 197022, Saint Petersburg, L’va Tolstogo St.. 6-8
E-mail address: ayaremenko@me.com,
gor.harutyunyan@gmail.com

Summary
In this study we sought to investigate the patients history database, underwent surgical treatment of removing pleomorphic adenoma amass form parotid gland (PG), also identifi replays of mass in the long-term follow-up period.
Material and methods: 391 case histories of patients with benign tumours of the (PG) were analysed in detail. 200 (51,1%) patients had a morphological diagnosis of a pleomorphic adenoma (PA). During postoperative follow-up, 39 (n=39) patients were examined, During the ultrasound (sonography) examination were identify 7 patients with replays of neoplasm of parotid salivary gland (pleomorphic adenoma?), the average age of the patients at the time of the examination was 41.6±13.4 years (men — 42 years old, women — 48.8+11.8 years). The sex ratio of patients were 6 females and 1 male patient, the average time of relapse occurred in the long-term follow-up period was 8.3 years. The morphological study of prevues surgery of 7 patients with relapse of neoplasm of parotid salivary gland (pleomorphic adenoma ?), revealed a predominance of mixoid component in all patients, out of 5 patients with PA, the fibrous capsule had a complete structure, the capsule is partially or completely thinned in 1 patient, and in 1 patient is completely absent.
Conclusion: By retrospective analysis of the data of patients who underwent to surgery of parotid gland surdested that the likelihood of tumor recurrence increases with the predominance of the myxold component in the structure of pleomorphic adenoma, especially in those where it is limited to the use of the method of ectracapsular enucleation, performed even in an extended version within the surface part of the parotid gland.
In addition, the risk of recurrence increases with morphological signs of complete or partial absence of the fibrous capsule of the PA.

Keywords: pleomorphic adenoma, parotid gland, recurrence, fibrous capsule, myxoid subtype.

For citation: Yaremenko A.I., Kutukova S.I., Harutyunyan G.G., Petrov N.L. The recurrence rate of pleomorphic adenoma in the long-term follow-up according to the clinic of maxillofacial surgery Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia. Stomatology for All / Int. Dental Review. 2020, no.4(93): 16-20 (In Russian). doi: 10.35556/idr-2020-4(93)16-20

References
1. Paches A.I., Tabolinovskaya T.D. Tumors of the salivary glands. Moscow: Practical Medicine, 2009, 470 p.
2. Abu-Ghanem Y, Mizrachi A, Popovtzer A, Abu-Ghanem N, Feinmesser R. Recurrent pleomorphic adenoma of the parotid gland: institutional experience and review of the literature. J Surg Oncol. 2016, 114(6): 714—718. doi:10.1002/jso.24392
3. Albergotti W.G. Extracapsular dissection for benign parotid tumors: a meta-analysis. The Laryngoscope. 2012, Vol.122, №9: 1954—1960.doi:10.1002/lary.23396
4. Bailey H. Parotidectomy: indications and results. BMJ. 1947, 1: 404—407.
5. Bankamp D.G., Bierhoff E. Proliferationsverhalten primärer und rezidivierter pleomorpher Adenome der Speicheldrüsen. Laryngorhinootologie. 1999, 78(2): 77—80. doi:10.1055/s-2007-996835.
6. Glas A.S., Hollema H., Nap R.E., Plukker J.T. Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland. Cancer. (2002) 94(8): 2211—2216. doi:10.1002/cncr.10445.
7. Li C., Xu Y., Zhang C., Sun C., Chen Y., Zhao H. et al. Modified partial superfi-cial parotidectomy versus conventional superficial parotidectomy improves treatment of pleomorphic adenoma of the parotid gland. Am J Surg. 2014, 208(1): 112—118. doi:10.1016/j.amjsurg.2013.08.036.
8. Donati M., Gandolfo L., Privitera A., Brancato G., Cardi F., Donati A. Superficial parotidectomy as first choice for parotid tumours. Chir. Ital. 2007 59(1) (JaneFeb): 91—97.
9. McGurk M. Benign parotid tumours. BMJ. 2004; 329: 1299—1300.doi:10.1136/bmj.329.7478.1299
10. McGurk M., Cascarini L. Controversies in the management of salivary gland disease. Oxford University Press, 2013.
11. Orita Y., Hamaya K., Miki K., Sugaya A., Hirai M., Nakai K. et al. Satellite tumors surrounding primary pleomorphic adenomas of the parotid gland. Eur Arch Otorhinolaryngol. 2010, 267(5): 801—806. doi:10.1007/s00405-009-1149-7.
12. Park G.C., Cho K.J., Kang J., Roh J.L., Choi S.H., Kim S.Y. et al. Relationship between histopathology of pleomorphic adenoma in the parotid gland and recurrence after superficial parotidectomy. J Surg Oncol. 2012, 106(8): 942—946. doi:10.1002/jso.23202.
13. Patey D.H., Thackray A.C. The treatment of parotid tumours in the light of a pathological study of parotidectomy material. Br J Surg. 1958, 45(193): 477—487. doi:10.1002/bjs.18004519314.
14. Becelli R., Perugini M., Mastellone P., Frati R., Surgical treatment of recurrences of pleomorphic adenoma of the parotid gland. J. Exp. Clin. Cancer Res. 2001, 20(4) (Dec): 487—489.
15. Seifert G, Langrock I, Donath K. Pathomorphologische Subklassifikation der pleomorphen Speicheldrusenadenome. Analyse von 310 pleomorphen Parotisadenomen. HNO. 1976, 24(12): 415—426.
16. Shang Xie, Kan Wang, Hui Xu, Rui-Xi Hua, Tian-Zhu Li, Xiao-Feng Shan, Zhi-Gang Cai. PRISMA—Extracapsular Dissection Versus Superficial Parotidectomy in Treatment of Benign Parotid Tumors: Evidence From 3194 Patients. Medicine. 2015, 94(34) August: 1237.
17. Spiro R.H. Salivary neoplasms: overview of a 35-year experience with 2807 patients. Head Neck Surg. 1986, 8: 177—184.
18. Witt R.L., Iro H., McGurk M. The role of extracapsular dissection for benign parotid tumors. Curr Otorhinolaryngol Rep. 2014, 2: 55—63.
19. Witt R.L: The Significance of the margin in Parotid surgery for pleomorphic adenoma. Laringoscope. 2002, 112: 2141—2154.
20. Wittekindt C., Streubel K., Arnold G., Stennert E., Guntinas-Lichius O. Recurrent pleomorphic adenoma of the parotid gland: analysis of 108 consecutive patients. Head Neck. 2007, 29(9): 822-828. doi:10.1002/ hed.20613.
21. Zbaren P., Stauffer E. Pleomorphic adenoma of the parotid gland: histopatho-logic analysis of the capsular characteristics of 218 tumors. Head Neck. 2007, 29(8): 751—757. doi:10.1002/hed.20569.